Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Pediatric Asthma
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

For children with asthma, exposure to indoor air pollution increases the risk of a serious asthma exacerbation, which can be life-threatening. Interventions aimed at improving indoor air quality, including use of a portable air cleaner with a high-efficiency particulate air (HEPA) filter, can reduce this risk, but the effectiveness, feasibility and acceptability of HEPA air cleaners varies by setting. In collaboration with a community health worker (CHW) delivered asthma education program, the investigators are conducting a randomized clinical trial to evaluate the effectiveness of HEPA air cleaners to improve indoor air quality and child asthma health in South King County of Washington state, a vulnerable community impacted by air pollution from airports and highway traffic. Key features of the Airports, Air Quality and Asthma (AAA) design include integration of CHWs into study procedures, including CHWs recruited from community-based organizations, into multiple aspects of the trial protocol. The investigators aim to recruit up to N=60 children with asthma randomized into intervention and control groups in a 1:1 ratio, conduct baseline assessments of indoor air quality and airway health, and collect repeated assessments of air quality and airway health during the three-month intervention period and after the trial concludes. Study findings will inform future approaches to integrate HEPA air cleaners into existing CHW asthma education programs in this and similar communities.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Double

Interventions / Regimen

  • Device: Portable air cleaner with HEPA filter — The Winix 9800 is a true HEPA air cleaner that has been AHAM (Association of Home Appliance Manufacturers) Verifide® for rooms that are 500 square feet in size. The air cleaner has a washable fine mesh pre-filter that captures large airborne particles, an activated carbon filter that reduces volatile organic compounds and odors, and a true HEPA filter that captures 99.99% of airborne allergens as small as 0.003 microns in size.
  • Device: Less effective portable air cleaner (no HEPA) — Winix 9800 air cleaner, with data logging energy use monitor is installed in the child's bedroom. In the sham group, the Winix 9800 true HEPA filter and activated carbon filter were removed. This was an internal modification and not visible to the user. The air cleaner still included a washable fine mesh pre-filter that captures large airborne particles.

Primary Outcomes

  • Symptom days over 7 days (Repeated measure, assessed on a weekly basis throughout the 3 month observation period.)
  • Change in Asthma Control Score (From the baseline visit until the end of study follow-up, 3 months later.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-06-01
Completion: 2027-06-01
Eligibility
Age: 6 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Washington
Principal Investigators:
  • Elena Austin, Sc.D. (PRINCIPAL_INVESTIGATOR) - University of Washington
Contact Information
Study Contact:
Christine Loftus, PhD, MPH
206-753-9079
cloftus@uw.edu
Elena Austin, ScD
206-221-6301
elaustin@uw.edu
University of Washington
Maria Tchong-French
206-685-0465
mtchong@uw.edu
University of Washington
Interventions
  • Device: Portable air cleaner with HEPA filter — The Winix 9800 is a true HEPA air cleaner that has been AHAM (Association of Home Appliance Manufacturers) Verifide® for rooms that are 500 square feet in size. The air cleaner has a washable fine mesh pre-filter that captures large airborne particles, an activated carbon filter that reduces volatile organic compounds and odors, and a true HEPA filter that captures 99.99% of airborne allergens as small as 0.003 microns in size.
  • Device: Less effective portable air cleaner (no HEPA) — Winix 9800 air cleaner, with data logging energy use monitor is installed in the child's bedroom. In the sham group, the Winix 9800 true HEPA filter and activated carbon filter were removed. This was an internal modification and not visible to the user. The air cleaner still included a washable fine mesh pre-filter that captures large airborne particles.
Study Locations (1 sites)
University of Washington, Seattle, Washington 98195 United States
Eligibility Criteria
Inclusion Criteria: * Child is 6-12 years old with a health care provider-diagnosed asthma. * Caregiver is comfortable in participating in all study activities in English (communicating with study staff by phone and completing online surveys). * Caregiver is familiar with the child's daily asthma health. * Residence within 10 miles of Seattle-Tacoma International Airport as determined by zip code * Child resides in caregiver's home at least five nights a week on a regular basis and has no plans to move in the next three months. Exclusion Criteria: * Child has severe asthma at baseline. Severe asthma was defined in consultation with pediatric pulmonologists to be caregiver-reported asthma symptoms every day over the past 14 days and/or two or more inpatient hospitalizations for asthma in the past 12 months. * Households were excluded if there were multiple individuals within the same household with asthma eligible for the King County CHW Asthma Program or had severe asthma.
Conditions Breast Cancer, Radiotherapy; Complicatio...
Phase Not Applicable
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The primary objective of the study is to describe the tolerance profile of radiation treatments performed during systemic treatment with new drugs (molecular targeted therapies, immunotherapy, others).

Design

Study type: Observational Observational model: Other Time perspective: Prospective

Interventions / Regimen

  • Radiation: Radiotherapy — Conventional fractionated radiotherapy, moderate hypofractionated radiotherapy, stereotactic radiotherapy (SABR)

Primary Outcomes

  • Toxicity of Radiotherapy Treatments (Baseline, at 3, 6 month, one year from the end of radiation treatment, then yearly up to 3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-05-17
Completion: 2029-05-17
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fondazione Policlinico Universitario Campus Bio-Medico
Contact Information
Study Contact:
Edy Ippolito, Prof
06225418011
e.ippolito@unicampus.it
Edy Ippolito, Prof
06/225418011
e.ippolito@unicampus.it
Radiation Oncology Department Fondazione Policlinico Campus BioMedico
Interventions
  • Radiation: Radiotherapy — Conventional fractionated radiotherapy, moderate hypofractionated radiotherapy, stereotactic radiotherapy (SABR)
Study Locations (1 sites)
Radiation Oncology Department Fondazione Policlinico Campus BioMedico, Rome, Italy 00128 Italy
Eligibility Criteria
Inclusion Criteria: * Patients suffering from stage IV breast cancer * Ongoing systemic treatment including: molecular targeted therapy, conjugated antibodies, monoclonal antibodies, tyrosine kinase inhibitors, immunotherapy (immunocheckpoint inhibitors) * Candidates for radiation treatment (both palliative and curative). Exclusion Criteria: * Previous radiation treatment on the same site * Absolute contraindications to radiotherapy * Systemic treatment administered as part of a clinical trial
Conditions Pulmonary Hypertension, Hypertension, Pu...
Phase Not Applicable
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Real-World Study of PADN for the Treatment of PAH

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Device: Enhancor™ Radiofrequency Catheter, Pulnovo Medical (Wuxi) CO., Ltd., Wuxi, Jiangsu, China — PADN: Contrast pulmonary artery (PA) angiography will be performed to localize the pulmonary artery bifurcation level and calculate the PA diameter. Once the anatomy deemed acceptable, the radiofrequency ablation catheter will be introduced into ostium of the left PA and the distal bifurcation area of the main PA. The catheter will be manoeuvred within the PA to allow energy delivery in a circumferential manner to ensure that the electrodes are tightly in contact with the endovascular surface. About three ablations at 45-55 # for 120 seconds each will be performed in ostium of the left PA and the distal bifurcation area of the main PA. For non-atrial fibrillation patients, dual antiplatelet therapy for 1 month after PADN is recommended. Patients with atrial fibrillation should continue new oral anticoagulants and patients who underwent metal valve replacement should continued oral warfarin anticoagulation according to guidelines, which could determined by the physician.

Primary Outcomes

  • Clinical worsening (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-03-19
Completion: 2028-12-30
Eligibility
Age: Not reported
Sex: ALL
Volunteers: Not specified
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Pulnovo Medical (Wuxi) Co., Ltd.
Contact Information
Study Contact:
Shao-liang Chen, MD
+86 13605157029
chmengx@126.com
The First Affiliated Hospital with Nanjing Medical University
Interventions
  • Device: Enhancor™ Radiofrequency Catheter, Pulnovo Medical (Wuxi) CO., Ltd., Wuxi, Jiangsu, China — PADN: Contrast pulmonary artery (PA) angiography will be performed to localize the pulmonary artery bifurcation level and calculate the PA diameter. Once the anatomy deemed acceptable, the radiofrequency ablation catheter will be introduced into ostium of the left PA and the distal bifurcation area of the main PA. The catheter will be manoeuvred within the PA to allow energy delivery in a circumferential manner to ensure that the electrodes are tightly in contact with the endovascular surface. About three ablations at 45-55 # for 120 seconds each will be performed in ostium of the left PA and the distal bifurcation area of the main PA. For non-atrial fibrillation patients, dual antiplatelet therapy for 1 month after PADN is recommended. Patients with atrial fibrillation should continue new oral anticoagulants and patients who underwent metal valve replacement should continued oral warfarin anticoagulation according to guidelines, which could determined by the physician.
Study Locations (1 sites)
The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu China
Eligibility Criteria
Inclusion Criteria: 1. Diagnosed with PAH and received PADN procedure since March 2024. 2. No contraindications to procedure. 3. Able to provide informed consent and authorize use of health/research data. 4. Compliant with treatment and follow-up requirements. Exclusion Criteria: None specified.
Conditions Lung Cancer (Diagnosis), Anxiety, Depres...
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this trial is to compare the impact of two outreach strategies (high touch vs. standard outreach) on a collaborative care program delivered via telehealth to patients with lung cancer.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: Double

Interventions / Regimen

  • Behavioral: High Touch Outreach — Gain-framed message, informational flyer, and direct request

Primary Outcomes

  • Reach - Completion of the intake assessment amongst referred patients. (Measured per patient up to 30 days after randomization.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-08-18
Completion: 2027-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Abramson Cancer Center at Penn Medicine
Collaborators: National Institutes of Health (NIH), National Cancer Institute (NCI)
Principal Investigators:
  • Alexandria Muench, PsyD (PRINCIPAL_INVESTIGATOR) - University of Pennsylvania
Contact Information
Study Contact:
Jennifer Steltz, MRA
215-573-2593
jennifer.steltz@pennmedicine.upenn.edu
Jocelyn Wainwright, MS
215-615-4226
jocelyn.wainwright@pennmedicine.upenn.edu
Alexandria Muench, PsyD
215-421-4491
amuench@pennmedicine.upenn.edu
Abramson Cancer Center at the University of Pennsylvania
Interventions
  • Behavioral: High Touch Outreach — Gain-framed message, informational flyer, and direct request
Study Locations (1 sites)
Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania 19104 United States
Eligibility Criteria
Inclusion Criteria: * Are aged 18 years or older. * Are currently being seen by Penn Medicine Thoracic Oncology for lung cancer treatment or survivorship care. * Are referred to collaborative care by a Penn Medicine Thoracic Oncology clinician for treatment of depression, anxiety, or other psycho-therapy services. Exclusion Criteria: * Are already receiving psycho-therapy treatment services outside of Penn Medicine's collaborative care program, Penn Integrated Care (PIC). * Have a significant and/or untreated medical and/or psychiatric co-morbidity (e.g., other cancers, schizophrenia, acute suicidal and/or homicidal ideation) that make them ineligible for the Penn CoCM program.
Conditions Diabetic Foot Ulcer Associated With Type...
Phase NA
Enrollment 84
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Diabetes mellitus (DM) is a common metabolic disease characterized by hyperglycemia, resulting from a deficiency or insufficiency of insulin. Diabetic foot ulcers (DFU), a late complication of diabetes, develop as a result of peripheral neuropathy, peripheral arterial disease, and trauma, negatively impacting individuals' quality of life and increasing the rate of hospitalization and amputation. While sharp debridement, one of the most effective methods in the management of diabetic foot ulcers, accelerates healing, it often causes pain and anxiety, which negatively impacts the treatment process. The physiological effects of anxiety include increased respiratory and heart rates, increased blood pressure, and prolonged procedure times. These effects can reduce patient compliance and complicate nursing care. Non-pharmacological interventions offer important alternatives for pain and anxiety management. One such method, the use of a stress ball, is based on a distraction technique and is used to reduce individuals' emotional and physiological stress levels. The literature has demonstrated the positive effects of stress balls during endoscopy, biopsy, and skin procedures. However, there is insufficient evidence regarding the use of stress balls during sharp debridement. Therefore, this study aimed to evaluate the effects of stress balls on pain, distress, and physiological parameters during surgical debridement in patients with diabetic foot ulcers. The results of this study are expected to contribute to nursing care.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Stress ball — The effects of stress balls on pain, distress and physiological parameters during surgical debridement in patients with diabetic foot ulcers will be investigated.

Primary Outcomes

  • Pain assessment (Before the Procedure, during the Procedure (10th minute), and baseline, after an average of 20-30 minutes)
  • Anxiety Assesment (The Distress Thermometer) (Before the Procedure and baseline, after an average of 20-30 minutes)
  • Physiological Parameters (heart rate, systolic and diastolic blood pressure, oxygen saturation and respiratory rate) (Before the Procedure, during the Procedure (10th minute), and baseline, after an average of 20-30 minutes)
  • Physiological Parameter: heart rate (Before the Procedure, during the Procedure (10th minute), and baseline, after an average of 20-30 minutes)
  • Physiological Parameters: systolic and diastolic blood pressure (Before the Procedure, during the Procedure (10th minute), and baseline, after an average of 20-30 minutes)
  • Physiological Parameter: oxygen saturation (Before the Procedure, during the Procedure (10th minute), and baseline, after an average of 20-30 minutes)
  • Physiological Parameter: respiratory rate (Before the Procedure, during the Procedure (10th minute), and baseline, after an average of 20-30 minutes)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-11-01
Completion: 2027-07-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 84 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Cukurova University
Principal Investigators:
  • DERYA GEZER, Asisstant Professor (STUDY_CHAIR) - Tarsus University
  • EZGİ MUTLUAY YAYLA, Asisstant Professor (STUDY_DIRECTOR) - Tarsus University
  • DUDU ALPTEKİN, Dr (STUDY_DIRECTOR) - CUKUROVA UNİVERSİTY
Contact Information
Study Contact:
Derya GEZER, Asisstant Professor
+905076990081
deryasahhin@hotmail.com
Ezgi Mutluay YAYLA, Asisstant Professor
ezgiyayla@tarsus.edu.tr
Tarsus University University
+90 (324) 600 00 33
bilgi@tarsus.edu.tr
Tarsus University
Interventions
  • Behavioral: Stress ball — The effects of stress balls on pain, distress and physiological parameters during surgical debridement in patients with diabetic foot ulcers will be investigated.
Study Locations (1 sites)
Tarsus University, Mersin, Tarsus 33400 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Patients who agree to participate in the study and sign the Informed Consent * Form will be included in the study. * They are over 18 years of age, * They are literate in Turkish, * They are undergoing surgical debridement for the first time, * They are receiving inpatient treatment in the ward, and * They have pain ≥1 on the Visual Analog Scale (VAS) before the procedure. Exclusion Criteria: * Patients who have a diagnosed psychiatric or mental illness, * Regular painkiller use and chronic pain, * Visual, hearing, perception, or communication problems, * Physically impaired (such as an open wound on the hand or lack of muscle strength to squeeze a stress ball), * Decided to undergo an intervention to reduce pain before debridement (such as local anesthesia, nerve blockade, opioid analgesics, etc.), * Used non-pharmacological methods to reduce pain before the procedure will not be included in the study.
Conditions Intrahepatic Cholangiocarcinoma (Icc), A...
Phase PHASE2
Enrollment 66
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a single-arm prospective phase II clinical trial to investigate the efficacy and safety of adjuvant concurrent chemoradiotherapy with simultaneous integrated boost following hepatectomy for intrahepatic cholangiocarcinoma with narrow margin (\<1cm) or nodal involvement. Eligibility patients will receive IMRT or VMAT. The prescription dose to high-risk area of tumor bed or positive lymph node was planned at 55-60Gy and the prescription dose to lymphatic drainage regions was planned at 40-45Gy in 20-25 fractions. During radiotherapy, patients will concurrently receive capecitabine (1600 mg/m² on days 1-14, every 21 days for 2 cycles). After radiotherapy, maintenance therapy with capecitabine will continue (2000 mg/m² on days 1-14, every 21 days for 6 cycles). For patients who cannot tolerate capecitabine, S-1 will be used as an alternative. The primary endpoint is 2-year recurrence-free survival. The secondary endpoints are 2-year overall survival, local-regional control rate and incidence of grade 3 or higher adverse events.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Adjuvant Concurrent Chemoradiotherapy with Simultaneous Integrated Boost — Eligibility patients will receive IMRT or VMAT. The prescription dose to high-risk area of tumor bed or positive lymph node was planned at 55-60Gy and the prescription dose to lymphatic drainage regions was planned at 40-45Gy in 20-25 fractions. During radiotherapy, patients will concurrently receive capecitabine (1600 mg/m² on days 1-14, every 21 days for 2 cycles). After radiotherapy, maintenance therapy with capecitabine will continue (2000 mg/m² on days 1-14, every 21 days for 6 cycles). For patients who cannot tolerate capecitabine, S-1 will be used as an alternative.

Primary Outcomes

  • Two-year Disease-free Survival (up to 24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-05-16
Completion: 2028-05-15
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 66 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Contact Information
Study Contact:
Bo Chen, MD
00861324000876
chenboo@outlook.com
Bo Chen, MD
00861324000876
chenboo@outlook.com
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Interventions
  • Radiation: Adjuvant Concurrent Chemoradiotherapy with Simultaneous Integrated Boost — Eligibility patients will receive IMRT or VMAT. The prescription dose to high-risk area of tumor bed or positive lymph node was planned at 55-60Gy and the prescription dose to lymphatic drainage regions was planned at 40-45Gy in 20-25 fractions. During radiotherapy, patients will concurrently receive capecitabine (1600 mg/m² on days 1-14, every 21 days for 2 cycles). After radiotherapy, maintenance therapy with capecitabine will continue (2000 mg/m² on days 1-14, every 21 days for 6 cycles). For patients who cannot tolerate capecitabine, S-1 will be used as an alternative.
Study Locations (1 sites)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China
Eligibility Criteria
Inclusion Criteria: * Age \> 18 years, \< 80 years * Patients with primary surgical treatment * Postoperative pathology confirmed intrahepatic cholangiocarcinoma * Postoperative pathology showing narrow resection margin (\<1cm) or positive lymph nodes * R0/R1 resection * Postoperative Child-Pugh score A5-B7 * Patients meeting either of the following conditions must undergo preoperative or pre-radiotherapy PET-CT to exclude distant metastasis or lymph node metastasis beyond the region from the lower esophagus to the aortic bifurcation 1. Lymph node metastasis accounting for \>50% of dissected nodes 2. Lymph node metastasis involving the paracardial region or below the renal vein level * Postoperative contrast-enhanced liver MRI to exclude Intrahepatic satellite nodules * Recovery from surgery with Eastern Cooperative Oncology Group performance status score of 0-2 * Estimated life expectancy \>3 months Exclusion Criteria: * History of malignancies, except for basal cell skin carcinoma and in situ carcinoma of the cervix * Had prior abdominal irradiation * Had prior liver transplantation * Had serious myocardial disease or renal failure * Had moderate or severe ascites with obvious symptoms 4 months after surgery * Duration from surgery ≥ 4 months
Conditions Health Risk Behaviors
Phase Not Applicable
Enrollment 265
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This cross-sectional observational study investigates the association between sleep quality, neck pain-related disability, and depression symptoms in young adults aged 18-28. The research reveals that poor sleep quality is significantly associated with higher depression scores and increased neck disability, emphasizing the need for integrative approaches targeting sleep quality to improve mental and musculoskeletal health outcomes.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Interventions / Regimen

  • Behavioral: Survey-Based Assessment — Participants completed standardized questionnaires including the Beck Depression Inventory (BDI), Pittsburgh Sleep Quality Index (PSQI), and Neck Disability Index (NDI) to evaluate psychological and functional outcomes associated with sleep quality. No experimental intervention was administered.

Primary Outcomes

  • Sleep Quality as Measured by the Pittsburgh Sleep Quality Index (PSQI) (Single assessment at baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-06-26
Completion: 2026-06-22
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: Not specified
Enrollment: 265 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Saglik Bilimleri Universitesi
Contact Information
Study Contact:
Esra Pehlivan
esra.pehlivan@sbu.edu.tr
Ayşegül Demirel
+90 539 308 99 38
demirelaysenur18@gmail.com
Esra Pehlivan, Associate Professor
02164189616
fztesrakambur@yahoo.com
Saglik Bilimleri Universitesi
Interventions
  • Behavioral: Survey-Based Assessment — Participants completed standardized questionnaires including the Beck Depression Inventory (BDI), Pittsburgh Sleep Quality Index (PSQI), and Neck Disability Index (NDI) to evaluate psychological and functional outcomes associated with sleep quality. No experimental intervention was administered.
Study Locations (1 sites)
Saglik Bilimleri Universitesi, Istanbul, Üsküdar 34668 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Aged 18-28 * No history of physical or psychological illness * Able to provide informed consent * Voluntarily agreed to participate Exclusion Criteria: * History of chronic illness or psychiatric disorder * Communication difficulties
Conditions Pulmonary Hypertension
Phase Not Applicable
Enrollment 1000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Pulmonary hypertension (PH) is a progressive cardiopulmonary disease characterized by elevated pulmonary artery pressure and vascular remodeling, which leads to right heart failure and increased mortality. Despite advances in diagnostics, risk stratification remains limited due to the disease's heterogeneity. This study aims to develop and validate a dynamic risk prediction model for PH by integrating multimodal data-including echocardiography, Cardiac MRI, PET-MR, ECG, biomarkers, and clinical features-using advanced machine learning algorithms. The study will establish a prospective cohort of PH patients to explore predictive markers, stratify prognosis, and provide a scientific basis for early warning and individualized management.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Time to clinical worsening (Up to 36 months)
  • All-cause mortality (Up to 36 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-06-27
Completion: 2029-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: First Affiliated Hospital of Fujian Medical University
Principal Investigators:
  • Dajun Chai, MD (PRINCIPAL_INVESTIGATOR) - First Affiliated Hospital of Fujian Medical University
Contact Information
Study Contact:
Dajun Chai, MD
0086059187981637
dajunchai-fy@fjmu.edu.cn
Biyun Chen, MSc
008613876168899
heraty@sina.com
Biyun Chen, MSc
008613876168899
heraty@sina.com
The First Affiliated Hospital of Fujian Medical University
Interventions
N/A
Study Locations (1 sites)
The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350011 China
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 years or older * Pulmonary artery systolic pressure (PASP) ≥35 mmHg as estimated by echocardiography * Provided written informed consent Exclusion Criteria: * Severe hepatic or renal insufficiency * Malignancy under active treatment * Severe infection * Active autoimmune disease * Major surgery within the past 3 months * Pregnant or breastfeeding women * Severe psychiatric disorder impairing ability to comply with the study protocol
Conditions Breast Cancer, Endometrial Cancer, Ovari...
Phase PHASE1, PHASE2
Enrollment 205
Locations 20 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: TER-2013 — Oral Capsules
  • Drug: Fulvestrant injection — Fulvestrant 500 mg Intramuscular Injection

Primary Outcomes

  • Number of Patients who Experience Dose-Limiting Toxicity (28 Days)
  • Number of patients who experience a treatment-related adverse event (Up to 2 years)
  • Objective Response Rate as assessed by RECIST v1.1 (Up to 2 years)
  • Duration of Response as assessed by RECIST v1.1 (Up to 2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2025-09-23
Completion: 2029-02-28
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 205 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Terremoto Biosciences Inc.
Contact Information
Study Contact:
Terremoto Biosciences, Inc. Clinical Trials Central Contact
888-682-1551
clinicaltrials@terremotobio.com
Felicia Lewis
626-218-5097
flewis@coh.org
City of Hope
Felicia Lewis
626-218-5097
flewis@coh.org
City of Hope, Irvine
Interventions
  • Drug: TER-2013 — Oral Capsules
  • Drug: Fulvestrant injection — Fulvestrant 500 mg Intramuscular Injection
Study Locations (20 sites)
City of Hope, Duarte, California 91010 United States
City of Hope, Irvine, Irvine, California 92618 United States
Florida Cancer Specialists - Lake Nona, Orlando, Florida 32827 United States
City of Hope, Chicago, Zion, Illinois 60099 United States
Massachusetts General Hospital, Boston, Massachusetts 02144 United States
Mayo Rochester, Rochester, Minnesota 55905 United States
Washington Univ. School of Medicine, St Louis, Missouri 63110 United States
Nebraska Cancer Specialists, Omaha, Nebraska 68130 United States
Carolina BioOncology Institute, Huntersville, North Carolina 28078 United States
UH Cleveland Medical Center, Cleveland, Ohio 44106 United States
Eligibility Criteria
Key Inclusion Criteria * Metastatic or locally advanced, unresectable disease * No available treatment with curative intent * Presence of lesions to be evaluated per RECIST v1.1: a. Dose Escalation: measurable or evaluable disease b. Cohort Expansion: measurable disease * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Adequate organ function * Advanced solid tumor malignancy harboring an eligible AKT/PI3K/PTEN pathway alteration detected by a sponsor approved test Key Inclusion Criteria for TER-2013 monotherapy arms: * Histologically confirmed diagnosis of: a. \[For TER-2013 dose escalation\]: solid tumor malignancy b. \[For TER-2013 cohort expansion\]: i. Cohort 1: ovarian cancer, cervical cancer, or squamous cell carcinoma of the head and neck, lung, or esophagus ii. Cohort 2: endometrial adenocarcinoma * Prior therapy: 1. \[For TER-2013 dose escalation\]: Received standard therapies appropriate for their tumor type and stage, unless contraindicated, intolerable, or patient refused 2. \[For TER-2013 cohort expansion\]: No more than 3 prior lines of treatment in the advanced setting Key Inclusion Criteria for TER-2013 and fulvestrant combination arms * Histologically confirmed diagnosis of: a. \[For TER-2013 + fulvestrant dose escalation\]: HR+/HER2- advanced unresectable or metastatic breast cancer b. \[For TER-2013 + fulvestrant cohort expansion\]: i. Received treatment with an AI containing regimen (single agent or in combination) ii. No more than 3 prior lines of treatment in the advanced unresectable or metastatic setting * Prior Therapy: a. \[For TER-2013 + fulvestrant dose escalation\]: Received treatment with an AI containing regimen (single agent or in combination) b. \[For TER-2013 + fulvestrant cohort expansion\]: i. Received treatment with an AI containing regimen (single agent or in combination) ii. No more than 3 prior lines of treatment in the advanced unresectable or metastatic setting Key Exclusion Criteria: * Known EGFR, KRAS, NRAS, HRAS, or BRAF oncogenic-driver co-mutation with PI3K/AKT/PTEN alteration * Clinically significant abnormalities of glucose metabolism * Active brain metastases or carcinomatous meningitis. * History of significant hemoptysis or hemorrhage within 4 weeks prior to first dose of study drug * Malabsorption syndrome, nausea and vomiting uncontrolled by medication, or disease significantly affecting gastrointestinal function likely to interfere with the delivery, absorption, or metabolism of TER-2013 * Prior therapy: 1. \[For TER-2013 monotherapy escalation\]: AKT inhibitor 2. \[For TER-2013 monotherapy expansion\]: AKT/PI3K/PTEN pathway inhibitor 3. \[For TER-2013 + fulvestrant combination expansion\]: AKT/PI3K/PTEN pathway inhibitor, fulvestrant and other SERDs, mTOR inhibitor; some PIK3CA-altered cohorts allow prior PI3K inhibitor. Other protocol-defined Inclusion/Exclusion Criteria apply
Conditions Posttraumatic Stress Disorder
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is a longitudinal, multicenter, single-blind, two-arm randomized controlled trial designed to evaluate the effectiveness of Multi-Modal Cognitive Processing Therapy (MMCPT) for individuals with posttraumatic stress disorder (PTSD). Participants will be randomly assigned to either the intervention group receiving MMCPT or a control group receiving treatment-as-usual (TAU). The intervention follows the standard CPT manual developed by Resick and consists of twelve weekly 90-minute individual sessions. The primary outcomes include PTSD symptom severity assessed by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) and the PTSD Checklist for DSM-5 (PCL-5). Secondary outcomes include sleep quality (actigraphy, PSQI), anxiety (STAI), depression (HDRS-17), remission rate, and posttraumatic growth (PTGI). Assessments will occur at baseline, mid-treatment, post-treatment, and at 3-, 6-, 9-, and 12-month follow-ups.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Cognitive Processing Therapy (CPT) — Participants will receive 12 weekly 90-minute individual sessions of Cognitive Processing Therapy (CPT) following the Resick manual. The intervention includes cognitive restructuring, trauma-related belief processing, and structured behavioral assignments. Sessions are delivered by trained therapists.
  • Other: Treatment as Usual (TAU) — Participants will receive routine outpatient psychiatric care as determined by clinicians. This may include medication, general supportive therapy, or psychoeducation, but will not include structured CPT sessions.

Primary Outcomes

  • Change in PTSD symptom severity (CAPS-5) (Baseline (Screening Visit, prior to randomization))
  • Change in PTSD symptoms (PCL-5) (Baseline, Week 6 ( Mid-treatment), Week 12 (Post-treatment), Month 3, Month 6, Month 9, and Month 12 follow-up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-01
Completion: 2027-12-31
Eligibility
Age: 20 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Far Eastern Memorial Hospital
Contact Information
Study Contact:
Hsin-I Liu, PhD, RN
+886-2-8966-7000
femh91095@femh.org.tw
Pei-Chuan Wu, MD
+886-2-8966-7000
femh91988@femh.org.tw
Hsin-I Liu, PhD, RN
+886-2-8966-7000
mimiko0523@gmail.com
Far Eastern Memorial Hospital
Interventions
  • Behavioral: Cognitive Processing Therapy (CPT) — Participants will receive 12 weekly 90-minute individual sessions of Cognitive Processing Therapy (CPT) following the Resick manual. The intervention includes cognitive restructuring, trauma-related belief processing, and structured behavioral assignments. Sessions are delivered by trained therapists.
  • Other: Treatment as Usual (TAU) — Participants will receive routine outpatient psychiatric care as determined by clinicians. This may include medication, general supportive therapy, or psychoeducation, but will not include structured CPT sessions.
Study Locations (1 sites)
Far Eastern Memorial Hospital, New Taipei City, Banqiao District 220 Taiwan
Eligibility Criteria
Inclusion Criteria: * Aged between 20 and 65 years * Diagnosed with PTSD according to DSM-5 criteria * Score ≥ 33 on the PTSD Checklist for DSM-5 (PCL-5) * Able to provide informed consent * Stable psychiatric medication regimen (if any) for at least 4 weeks prior to enrollment Exclusion Criteria: * Diagnosed with schizophrenia, schizoaffective disorder, or bipolar I disorder * Current substance dependence or abuse within the past 6 months * Severe suicidal ideation or suicide attempt in the past 6 months * Cognitive impairment or neurological disorder affecting participation * Concurrent participation in other psychological treatment for PTSD
Conditions Breast Neoplasms
Phase PHASE3
Enrollment 1000
Locations 199 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally advanced or metastatic. * HR positive (HR+) means the cancer cells have proteins that attach to estrogen or progesterone (hormones) which help the cancer to grow and spread * HER2 negative (HER2-) means the cancer cells have a low amount of a protein called HER2 * Unresectable locally advanced means the cancer cannot be completely removed by surgery and has spread into nearby tissue or muscles * Metastatic means the cancer has spread to other parts of the body Treatment for this type of breast cancer usually includes endocrine therapy (ET) and sometimes a second treatment. The main goal of this study is to learn if people who receive patritumab deruxtecan (also known as HER3-DXd and MK-1022) live longer overall or without the cancer growing/spreading, compared to people who receive chemotherapy or a different drug called trastuzumab deruxtecan.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Biological: Patritumab deruxtecan — Administered via intravenous (IV) infusion
  • Drug: Paclitaxel — Administered via IV infusion
  • Drug: Nab-paclitaxel — Administered via IV infusion
  • Drug: Capecitabine — Administered via oral tablets
  • Drug: Liposomal doxorubicin — Administered via IV infusion
  • Biological: Trastuzumab deruxtecan — Administered via IV infusion

Primary Outcomes

  • Progression Free Survival (PFS) (Up to approximately 45 months)
  • Overall Survival (OS) (Up to approximately 85 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-07-21
Completion: 2033-07-14
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Merck Sharp & Dohme LLC
Collaborators: Daiichi Sankyo
Principal Investigators:
  • Medical Director (STUDY_DIRECTOR) - Merck Sharp & Dohme LLC
Contact Information
Study Contact:
Toll Free Number
1-888-577-8839
Trialsites@msd.com
Study Coordinator
251-607-5283
Southern Cancer Center (SCC) ( Site 8000)
Study Coordinator
520-626-0191
The University of Arizona Cancer Center - North Campus ( Site 0055)
Interventions
  • Biological: Patritumab deruxtecan — Administered via intravenous (IV) infusion
  • Drug: Paclitaxel — Administered via IV infusion
  • Drug: Nab-paclitaxel — Administered via IV infusion
  • Drug: Capecitabine — Administered via oral tablets
  • Drug: Liposomal doxorubicin — Administered via IV infusion
Study Locations (199 sites)
Southern Cancer Center (SCC) ( Site 8000), Daphne, Alabama 36526 United States
The University of Arizona Cancer Center - North Campus ( Site 0055), Tucson, Arizona 85719 United States
Los Angeles Hematology Oncology Medical Group ( Site 0026), Los Angeles, California 90017 United States
Hoag Memorial Hospital Presbyterian ( Site 0025), Newport Beach, California 92663 United States
St. Marys Hospital and Regional Medical Center-SCL Health Cancer Centers of Colorado ( Site 0021), Grand Junction, Colorado 81501 United States
Medical Oncology Hematology Consultants (MOHC) ( Site 8002), Newark, Delaware 19713 United States
AdventHealth Medical Group Oncology and Hematology at Altamonte ( Site 0024), Altamonte Springs, Florida 32701 United States
Comprehensive Hematology Oncology ( Site 0060), St. Petersburg, Florida 33709 United States
Baptist Health Lexington ( Site 0050), Lexington, Kentucky 40503 United States
Baptist Health Hamburg ( Site 0071), Lexington, Kentucky 40509 United States
Eligibility Criteria
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has a diagnosis of hormone receptor positive (HR+)/human epidermal growth factor receptor 2 (HER2)- invasive breast carcinoma that is either locally advanced disease not amenable to resection with curative intent (herein called unresectable) or metastatic disease not treatable with curative intent * Has centrally-confirmed HR+ and HER2- results and human epidermal growth factor receptor 3 (HER3) evaluable results from a biopsy obtained from a distant metastatic site or a locally advanced lesion on or after the most recent line of therapy (with certain exceptions) * Must have had progression or recurrence on prior cyclin-dependent kinase (CDK)4/6 inhibitor + endocrine therapy (ET) with one of the following: * Radiographic disease progression, as assessed by the investigator, on CDK4/6 inhibitor + ET as 1L for treatment of unresectable locally advanced or metastatic HR+/HER2- breast cancer. CDK4/6 inhibitor + ET must be the only line of therapy received in the advanced setting, or * Disease recurrence, either radiographic and/or confirmed histologically via biopsy as assessed by the investigator, while on adjuvant ET in combination with a CDK4/6 inhibitor OR within 24 months from the date of last dose of adjuvant CDK4/6 inhibitor * Has measurable disease per RECIST 1.1 as assessed by the local site investigator/radiology * Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy * Has an Eastern Cooperative Oncology Group performance status of 0 or 1 assessed within 7 days before randomization Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has breast cancer amenable to treatment with curative intent * Is eligible to receive additional endocrine-based treatment in the advanced setting as determined by the investigator * Has a known germline breast cancer gene (BRCA) mutation (deleterious or suspected deleterious) where poly (ADP-ribose) polymerase (PARP) inhibitor(s) is a potential treatment option * Has current visceral crisis or is at risk for impending visceral crisis that has or may cause imminent organ compromise and/or other life-threatening complications * Has any of the following: a pulse oximeter reading \<92% at rest, or requires intermittent supplemental oxygen, or requires chronic supplemental oxygen * Has uncontrolled, significant cardiovascular disease or cerebrovascular disease * Has ≥Grade 2 peripheral neuropathy. * Has clinically significant corneal disease * Has received prior chemotherapy for unresectable locally advanced or metastatic breast cancer * Has received prior treatment with an anti-HER3 antibody and/or antibody-drug conjugate that consists of a topoisomerase I inhibitor (eg, T-DXd) or any other topoisomerase I inhibitor therapy * Has received prior systemic anticancer therapy within 4 weeks (or 5 half-lives, whichever is shorter) before randomization; participants previously treated with ET plus a CDK4/6 inhibitor may participate as long as at least 2 weeks have elapsed since the last dose of therapy was administered * Has received prior radiotherapy for non-central nervous system disease, or required corticosteroids for radiation-related toxicities, within 14 days of the first dose of study intervention * Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy * Has known additional malignancy that is progressing or has required active treatment within the past 3 years * Has history of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids, has current pneumonitis/interstitial lung disease, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at Screening * Has severe hypersensitivity (≥Grade 3) to HER3-DXd and/or any of its excipients * Has severe hypersensitivity (≥Grade 3) to all the available TPC and/or any of their excipients
Conditions Breast Cancer, Breast Reconstruction, Ra...
Phase PHASE3
Enrollment 506
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study investigates the safety and efficacy of hypofractionated radiotherapy (HFRT) versus conventional fractionated radiotherapy (CFRT) in breast cancer patients undergoing total mastectomy with prosthetic reconstruction. Study Design Population: Patients with high-risk breast cancer after mastectomy and immediate implant reconstruction. Intervention: HFRT Arm: 43.5 Gy in 15 fractions (2.9 Gy/fraction, 3 weeks). Control Arm: CFRT (50 Gy in 25 fractions, 2 Gy/fraction, 5 weeks). Endpoints Primary: Reconstruction failure rate (e.g., implant removal, capsular contracture)

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: hypofractionated radiotherapy — 43.5 Gy in 15 fractions (2.9 Gy/fraction, 3 weeks)
  • Radiation: conventional fractionated radiotherapy — 50 Gy in 25 fractions, 2 Gy/fraction, 5 weeks

Primary Outcomes

  • Reconstruction Failure Rate (2 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-03-27
Completion: 2030-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 506 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Contact Information
Study Contact:
Xuran Zhao, MD
86-13661135602
923791362@qq.com
Yirui Zhai, MD
86-18610168510
januarywind@163.com
Shulian Wang, MD
8810-87787659
wangsl@cicams.ac.cn
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Interventions
  • Radiation: hypofractionated radiotherapy — 43.5 Gy in 15 fractions (2.9 Gy/fraction, 3 weeks)
  • Radiation: conventional fractionated radiotherapy — 50 Gy in 25 fractions, 2 Gy/fraction, 5 weeks
Study Locations (1 sites)
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Province 10000 China
Eligibility Criteria
Inclusion Criteria: * Female, aged 18-75 years * Karnofsky Performance Status ≥60 * Histopathologically confirmed invasive breast adenocarcinoma * Total mastectomy \[with or without nipple-areolar complex preservation\] + axillary dissection/sentinel lymph node biopsy + implant/expander placement R0 resection with negative margins * pT3 or N2-3 disease; or pT1-2N1 * No distant metastasis * Completed standard neoadjuvant/adjuvant chemotherapy cycles * ≤8 weeks post-chemotherapy or ≤12 weeks post-surgery if no chemotherapy * Signed informed consent Exclusion Criteria: * Prior radiotherapy to chest wall or nodal regions * Pregnancy or lactation * T4 stage disease * Autologous breast reconstruction of the irradiated breast * Pre-radiotherapy local/regional/distant metastasis * Grade ≥3 implant-related adverse events irreversible before radiotherapy * Bilateral breast cancer requiring bilateral radiotherapy * Concurrent/secondary malignancy with disease-free interval \<5 years \[except non-melanoma skin cancer, papillary/follicular thyroid cancer, or cervical carcinoma in situ\] * Active collagen vascular disease, e.g., SLE, scleroderma * Uncontrolled comorbidities: acute cardiovascular disease, substance abuse, or psychiatric disorders